Rolling Returns
Emcure Pharmaceuticals Ltd.
Every 1-year stretch EMCURE has been through — 14 of them, each starting a month after the last. The median returned 23.6% a year, the worst -12.7%, the best 64.8%. A single headline CAGR hides all of that.
Every Holding Period
A rolling window is every possible start date, not one. A five-year window starting in January is a different investment from one starting in February, and over twenty years there are a couple of hundred of them. What follows is the full spread of what each holding period actually produced.
Across 14 separate 1-year holding periods, the median returned 23.6% a year. The worst lost 12.7% a year and the best made 64.8%.
Worst start: September 2024 — -12.7% a year for the 1 years that followed.
Best start: April 2025 — 64.8% a year.
Against the Nifty 50: EMCURE came out ahead in 71.4% of the 14 windows both series cover.
Windows step forward one month at a time and are measured on month-end adjusted closing prices, so dividends are treated as reinvested. Overlapping windows share months by construction — that is what makes the spread a description of this stock's history rather than a sample of independent trials.
Against The Index
Beating an index once is a result. Beating it across most of the periods an investor could have picked is a pattern. Over 1-year windows, EMCURE finished ahead of the Nifty 50 in 71.4% of the 14 periods both series cover.
1-year windows
Ahead in 71.4% of 14 periods.
Each window is compared against the index over the identical calendar months, on the same adjusted basis — not against an assumed rate of return.
How This Is Calculated
Windows step forward one month at a time, so they share most of their months with each other. That is what makes this a description of EMCURE's actual history rather than a set of independent trials — and why the spread should not be read as a probability.
Measured on month-end closing prices adjusted for dividends and splits, so dividends count as reinvested. A window that opened or closed mid-month would differ a little in either direction.
EMCUREis in today's Nifty 500 universe. Companies that delisted or collapsed are not on this site at all, so the worst outcome shown here is the worst among the survivors.
Measured on data to 2026-08-31, from 2024-07-01. Full definitions are on our methodology page.
HELP CENTER
Everything you need to know about this page and the data presented.
Over 1 year, Emcure Pharmaceuticals Ltd. has been through 14 separate 1 year holding periods — one starting every month. The median returned 23.6% a year, the worst -12.7% and the best 64.8%. A rolling return measures every possible start date instead of one, which is why it answers a question a single headline CAGR cannot: how much the outcome depended on when you happened to buy.
Yes. 28.6% of the 14 1 year periods on record ended below where they started, and the worst of them lost 12.7% a year — the stretch beginning September 2024. The median period returned 23.6% a year.
In 71.4% of the 14 1 year periods both series cover. Each window is compared against the index over the identical months, not against an assumed index return, so the comparison is a like-for-like record rather than a model.
Windows step forward one month at a time on month-end closing prices adjusted for dividends and stock splits, so dividends are treated as reinvested. A window length is only published once there are at least twelve complete windows behind it — fewer than that describes an anecdote, not a distribution. Overlapping windows share months by construction, which is what makes this a description of the actual history of Emcure Pharmaceuticals Ltd. rather than a sample of independent trials. Companies that delisted are not on this site at all, a survivorship bias worth holding in mind.
That is not a question this page answers, and we do not make recommendations. What it can show you is the full range of what every holding period in the listed history of Emcure Pharmaceuticals Ltd. actually produced — including the worst ones, which most performance figures leave out. Those are records of what happened, not forecasts. A stock that never had a losing decade may still have one, and holding a single company is a materially different risk from holding an index.
Explore Further
EMCURE drawdowns and all-time high
The worst fall on record, how long recovery took, and how far the price sits below its peak.
EMCURE SIP returns
What a monthly investment would have produced, backtested rather than assumed.
EMCURE overview
Price history, wealth journey and how it compares with the index.
Rolling returns for every stock
Run the same question against any company we track.
ReturnScreener is an educational research platform and is not a SEBI-registered investment adviser. Everything on this page is a record of what historical prices did, not a projection and not a recommendation. Past performance does not guarantee future returns. See our methodology and disclaimer.